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	1. Summary 
 
Title: Long-term Consequences of Polycystic Ovary Syndrome 
Author: Monika Elisabeth Crumbach 
 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
women of reproductive age. It shares many features with the metabolic syndrome 
(insulin resistance, an increase in body mass index, changes in lipidogram, increases 
in C-reactive protein due to chronic inflammation). As a long-term consequence, 
development of cardiovascular disease (CVD) is likely. 
The purpose of this retrospective observational study was to explore if 
cardiometabolic risk factors (BMI, HOMA-IR, total cholesterol, TG, LDL-C, HDL-C, 
CRP) worsen over time in PCOS patients. The data of 36 PCOS patients aged 26.5 ± 
6.4, in whom the diagnosis was made according to the Rotterdam criteria, was included 
in the study. The metabolic parameters were taken from hospital records of University 
Hospital Petrova Gynecological Clinic in Zagreb, Croatia. We included laboratory 
values measured at the starting point of the study, in 2007, and after nine years, in 
2016.  
 No significant worsening of cardiometabolic risk factors was found after the nine 
years. Only the percentage of PCOS patients with a BMI > 25 increased from 25.0% 
to 33.3% (P = 0.002). 
 Further studies should be conducted with a larger sample size and longer 
duration of observation.  
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	2. Sažetak 
 
Titula: Dugoročne Posljedice Sindroma Policističnih Jajnika 
Autor: Monika Elisabeth Crumbach 
 
Sindrom policističnih jajnika (PCOS) najčešći je endokrinološki poremećaj u 
žena reprodukcijske dobi. Ovaj sindrom dijeli mnoge karakteristike  metaboličkog 
sindroma poput inzulinske rezistencije, povišenog indeksa tjelesne mase, poremećaja 
vrijednosti lipida, te povišenih vrijednosti C-reaktivnog proteina. S obzirom da ovi rizični 
metabolički parametri često prate PCOS, očekivana je veća vjerojatnost neželjenih 
kardiovaskularnih događaja kao dugoročna posljedica PCOS-a. 
Cilj je ove retrospektivne opservacijske studije bio istražiti dolazi li tijekom 
vremena do pogoršanja kardiometaboličkih rizičnih čimbenika (BMI, HOMA-IR, ukupni 
kolesterol, trigliceridi, LDL-C, HDL-C,CRP). Analizirani su podaci 36 bolesnica, 
prosječne dobi 26.5 ± 6.4, kod kojih je dijagnoza PCOS-a postavljena prema 
Rotterdamskim kriterijima 2007 godine. Podaci o vrijednostima različitih metaboličkih 
parametara analizirani su iz bolničkog informacijskog sustava Klinike za ženske bolesti 
i porode KBC-a i Medicinskog fakulteta Sveučilišta u Zagrebu. U analizu smo uključili 
one laboratorijske nalaze koji su izrađeni 2007. godine i ponovno 2016. odnosno nakon 
vremenskog intervala od devet godina. 
Nije nađeno značajno pogoršanje kardiometaboličkih rizičnih čimbenika u 
periodu od devet godina. Zabilježeno je povećanje udjela pacijentica s ITM > 25 kg/m2 
(P = 0.002). 
 Potrebne su daljnje studije koje će uključiti veći broj bolesnica s PCOS-om sa 
dužim vremenskim periodom praćenja.  
 
 
Ključne riječi: Sindrom policističnih jajnika, kardiometabolički rizici  
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2. Preface 
 
This graduate thesis is based on data collection of women with Polycystic ovary 
syndrome (PCOS), over the course of nine years, from 2007 to 2016. The sample of 
women consists of patients who have been followed by Assoc. Prof. Dinka Pavičić 
Baldani and Assist. Prof. Lana Škrgatić over this time period. The thesis is concerned 
with certain parameters of cardiometabolic risk associated with PCOS, their change 
over this nine-year period, due to their association with development of cardiovascular 
disease (CVD) over the years. The parameters associated with an increased risk of 
developing CVD considered in this text are increased body mass index (BMI) and 
waist-hip ratio (WHR), homeostatic model assessment of insulin resistance (HOMA-
IR), changes in lipidogram (total cholesterol [total-C], triglycerides [TG], low density 
lipoprotein cholesterol [LDL-C], and high density lipoprotein cholesterol [HDL-C]), and 
C-reactive protein (CRP) as a strong independent predictor for development of CVD. 
 
This thesis was a prerequisite for the completion of the Medical Studies in English 
Program at the University of Zagreb, School of Medicine. The author of the thesis is 
Monika Elisabeth Crumbach, who wrote it with the assistance of her mentor, Assist. 
Prof. Lana Škrgatić.  
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3. Hypothesis 
 
Cardiometabolic risk factors (BMI, HOMA-IR, total cholesterol, TG, LDL-C, HDL-C, 
CRP) worsen over time in PCOS patients.  
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4. Objectives 
 
The aim of the present study was to evaluate whether there is a worsening of 
various cardiometabolic risk factors in PCOS patients in the time frame of nine years. 
The data was collected from the hospital records of the University Hospital Petrova 
Gynecological Clinic in Zagreb, Croatia. Determining the changes in different 
cardiometabolic risk parameters could help in the development of preventive measures 
for this large group of affected women and would be of great help in their screening, 
treatment, and improvement of morbidity and mortality. 
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5. Introduction 
 
PCOS, also known as Stein-Leventhal syndrome, is the most common 
endocrine disorder in women of reproductive age.  
As defined by the Rotterdam criteria [1, 2], for the diagnosis of PCOS, more than two 
of the following are required: oligo-/anovulation, clinical and/or biochemical signs of 
hyperandrogenism, and polycystic ovaries on ultrasound, after exclusion of other 
diseases that manifest similarly, such as congenital adrenal hyperplasia, 
hyperprolactinemia, androgen secreting tumors, thyroid dysfunction, and Cushing 
syndrome. 
PCOS is often associated with an increased risk in developing CVD as a long-
term consequence. The disorder shares many features with the metabolic syndrome 
(insulin resistance [IR], an increase in BMI, changes in lipidogram, increase in CRP 
due to chronic inflammation), and is therefore associated with an increase in 
cardiometabolic risk factors [3, 4]. These risk factors are closely interconnected and 
an understanding is essential for evaluating the overall risk. 
 Obesity and an increased BMI is a common but non-essential feature of PCOS. 
Even in non-obese patients with PCOS, an increased BMI and increase in WHR is 
evident [3]. It is well-known that women with PCOS tend to have a centripetal fat 
distribution, with an accumulation of visceral fat in the abdominal region [5]. Increased 
intra-abdominal obesity, leads to an increase in lipolysis of the metabolically more 
active visceral fat, and therefore in an increase of free fatty acids which further 
contributes to IR in said patients. Insulin signaling is inhibited by increased serine 
phosphorylation induced by the cytokine tumor necrosis factor-a (TNF-a) produced by 
the released free fatty acids. This leads to IR, which is a common feature in obese and 
in a smaller proportion of lean patients with PCOS [3, 6]. The present visceral fat does 
not only contribute to the development of IR, but also produces a state of chronic low-
grade inflammation. An increase in BMI and WHR are well-recognized risk factors for 
developing CVD. Both obesity and PCOS contribute independently to the arterial 
stiffness connecting PCOS to CVD [7]. Ketel et al. [7] concluded that obesity has a 
stronger association with increased arterial stiffness than PCOS, and the focus in 
prevention of CVD should lie in central fat mass reduction in obese women with PCOS. 
Yusuf et al. [8] compared the odds ratio (OR) for developing a myocardial infarction 
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(MI) in patients with a WHR in the upper tertile with those in the lower tertile. He found 
that those in the upper tertile have an OR of around 2. 
IR causes hyperinsulinemia, which contributes to hyperandrogenism through a 
resulting increase in androgen production by the ovaries, and inhibition of steroid 
hormone binding globulin (SHBG) production in the liver. This mechanism further 
aggravates the syndrome [3]. There is an overall prevalence of IR in women with 
PCOS, partly independent of the presence of obesity. According to Randeva et al. [9] 
both lean (30%) and obese (70%) women with PCOS show decreased insulin 
sensitivity, compared to a control group of women of equal age. Women with PCOS of 
all ages commonly suffer from IR, hyperinsulinemia and diabetes [4]. Dunaif et al. [6] 
found that IR is caused by excessive serine phosphorylation of insulin receptors, which 
leads to decreased protein kinase activity. Serine phosphorylation of the regulatory 
enzyme P450c17 involved in androgen metabolism further contributes to 
hyperandrogenism present in women with PCOS [3, 9]. Free fatty acids excessively 
released by lipolysis in obese patients is a stimulant factor for serine phosphorylation 
[3, 9]. 
 Dyslipidemia is the most common metabolic abnormality in PCOS [10]. Both 
lean and obese women with PCOS present with dyslipidemia [9]. The lipidogram 
shows an increase in TGs and LDL-C, while HDL-C is decreased [3 ,9, 10]. The change 
in lipid profile is associated with the presence of hyperinsulinemia and IR [3], similar to 
the changes found in type 2 diabetes [9]. IR causes an increase in very-low-density-
lipoproteins, chylomicrons, TG, and an increased clearance of apolipoprotein-A, which 
leads to a general decrease of the cardioprotective HDL in the circulation [5]. Randeva 
et al. [9] observed that there is a 1.8-fold increase in risk of developing dyslipidemia in 
women with PCOS in comparison to their relatives. Particularly increased LDL-C and 
low HDL-C levels predict the development of coronary artery disease according to the 
Framingham study [11]. 
 A powerful independent risk factor for the development of CVD is CRP, a marker 
of chronic inflammation [12]. As mentioned above, visceral obesity leads to a state of 
chronic low-grade inflammation. CRP also acts as a mediator in the atherosclerotic 
process itself [13]. Therefore, high CRP levels in women with PCOS also correlate with 
an increased risk of developing early CVD in these patients. Amongst others reasons 
for high CRP levels in women with PCOS is its production by pro-inflammatory 
cytokines, such as Interleukin-6 and TNF-a. The association of cardiometabolic 
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syndrome with PCOS is already well established and has also been the subject of 
other studies. Its importance is growing, especially in the light of the increased 
incidence of sedentary lifestyles and obesity demographics [14, 15]. Only a few studies 
have looked into the long-term changes of cardiometabolic risk parameters over time. 
Therefore, the aim of the present study was to evaluate whether there is a difference 
between various cardiometabolic risk factors in PCOS patients in the time frame of 
nine years.  
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6. Patients and Methods 
 
To examine the association between various cardiometabolic risk factors and 
PCOS, we performed a retrospective observational study. The data of 36 PCOS 
patients aged 26.5 ± 6.4 in whom the diagnosis was made according to the Rotterdam 
criteria [1, 2] was included in the study. The patient data was only included if they 
contained measurements of BMI, HOMA-IR, total-C, TG, LDL-C, HDL-C, and CRP in 
the years 2007 and 2016, respectively. The data on FSH, LH, total testosterone, free 
testosterone, A, DHEA-S, and SHBG was only extracted from the medical records 
when it was used for the diagnosis of PCOS in 2007.  The data was obtained from the 
hospital records of the Human Reproduction Unit Outpatient Clinic of the 
Gynecological Hospital Petrova in Zagreb, Croatia. 
The data values were expressed as the means ± standard deviation, and categorical 
data as percentages. The non-parametric Wilcoxon Signed Rank Test was used to test 
the differences between continuous variables, while Pearsons c2-test was used for 
categorical variables. Categorical data was also presented graphically. All statistical 
analyses were done using the SPSS for Windows (version 22.0; SPSS Inc., Chicago, 
IL, USA). A P-value < 0.05 was considered statistically significant. 
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7. Results 
 
The hormonal parameters which aided in the diagnosis of PCOS patients from 
the year 2007 are presented in table 1. The table shows that 25% (9 out of 36) of the 
patients had a BMI above 25 kg/m2, and were therefore overweight per definition. 
Almost 85% of patients had hyperandrogenism. 
 
Table 1. Basic characteristics of PCOS patients included in the observational study. 
Data extracted from medical records in 2007. 
 N = 36  
Age (years) 26.5 ± 6.4 
BMI (kg/m2) 23.5 ± 2.3 
BMI > 25 (kg/m2) (%) 25 
FSH (IU/L) 3.4 ± 1.0 
LH (IU/L) 8.3 ± 4.2 
tT (nmol/L) 2.3 ± 0.9 
tT > 2.0 (nmol/L) (%) 52.8 
freeT (pmol/L) 44.4± 28.3 
freeT > 26.0 (pmol/L) (%) 83.3 
A (nmol/L) 10.8±4.5 
DHEA-S (μmol/L) 6.5±2.6 
SHBG (nmol/L) 43.7±37.5 
 
 
We found no statistically significant differences in cardiometabolic risk factors in the 
year 2007 compared to 2016 using the Wilcoxon Signed Rank Test (P < 0.05), except 
in BMI values, which are presented in table 2. The percentage of PCOS patients with 
a BMI > 25 increased from 25.0% to 33.3% (N = 36, P = 0.002). IR was present in 10 
(27.8%) PCOS patients in 2007, and in 11 (30.6%) patients in 2016. Hence, the 
changes were not statistically significant (P = 0.611). In 2007 hypercholesterolemia 
was measured in only four patients out of 36, while in 2016 the number increased to 
seven out of 36 patients (P = 0.163). The number of patients with hypertriglyceridemia 
increased from 12 patients in 2007 to 13 patients in 2016 (P = 0.447). In 2007, six 
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women with PCOS had an HDL-C < 1.2 nmol/L, while in 2016 the number only 
increased to seven (P = 0.671). In a similar manner, LDL-C values > 3nmol/L were 
measured in 2007 in five PCOS patients, and in 2016 in six patients (P = 0.550). CRP 
levels in 2007 were measured to be 2.0 ± 0.4 mg/L and until 2016 barely increased to 
2.1 ± 0.6 mg/L (P = 0.574).  
 
 
Table 2. Differences between concentrations of various metabolites in PCOS patients 
in 2007 compared to 2016. 
 PCOS (N = 36) 
2007. 
PCOS (N = 36) 
2016. 
P-value1 
BMI (kg/m2) 23.5 ± 2.3 24.47 ± 2.8 <0.001 
BMI > 25 (kg/m2) (%) 25.0 33.3 0.002 
glucose (mmol/L) 4.4±0.5 4.5 ± 0.5 0.900 
insulin (mIU/L) 12.7±10.0 11.9 ± 9.5 0.928 
GIR 8.9±6.0 9.6 ± 6.5 0.550 
HOMA-IR 2.6±2.3 2.5 ± 2.2 0.967 
HOMA-IR > 2.5 (%) 27.8 30.6 0.611 
Total-C (nmol/L) 4.5±0.3 4.5 ± 0.4 0.644 
Total-C > 5 nmol/L 11.1 19.4 0.163 
TG (nmol/L) 1.4±0.4 1.4 ± 0.3 0.905 
TG >1.7 nmol/L (%) 33.3 36.1 0.447 
HDL – C (nmol/L) 1.6±0.3 1.5 ± 0.2 0.726 
HDL-C < 1.2 nmol/L 16.7 19.4 0.671 
LDL-C (nmol/L) 2.3±0.5 2.4 ± 0.6 0.550 
LDL-C > 3 nmol/L 13.9 16.7 0.378 
CRP (mg/L) 2.0±0.4 2.1 ± 0.6 0.574 
1Wilcoxon Signed Rank Test, Chi square test 
 
 
Figure 1 graphically presents the values listed in table 2, showing an increasing trend 
in all measured cardiometabolic parameters, but this did not reach statistical 
significance. BMI shows the only significant change with an increase over time (P = 
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0.002). The biggest change observed among metabolic parameters was in serum 
levels of total-C, but also insignificant (P = 0.163).  
 
 
 
Figure 1. Graphic presentation of the differences in metabolite concentrations in 
2007 compared with 2016.  
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8. Discussion 
 
This retrospective observational study followed up different cardiometabolic 
parameters (BMI, HOMA-IR, total-C, TG, LDL-C, HDL-C, CRP) of 36 PCOS patients 
of the Human Reproduction Unit of the Gynecological Hospital Petrova in Zagreb, 
Croatia. The parameters were recorded and re-assessed after a time period of nine 
years from 2007 to 2016. Only a few studies have examined the changes of 
cardiometabolic risk factors over time so far. Our results showed that there was no 
significant difference in cardiometabolic parameters after that time. Therefore, our 
hypothesis that the cardiometabolic risk changes over time was not supported. 
 
Body Mass Index 
As presented in the results, BMI was the only cardiometabolic parameter with a 
statistically significant change over the nine years. The number of women with PCOS 
with a BMI > 25kg/m2 increased from nine to 12 out of 36 (P = 0.002). Even though the 
number increased as we predicted, we expected an even bigger increase associated 
with PCOS. The changes observed here could also be purely related to increases of 
BMI commonly associated with aging. According to a Norwegian study [16] which 
started in the mid-80s women aged 20-29 increased their weight on average by 7.3kg 
over a period of 11 years. Another Norwegian study [17] examined increases in BMI 
by level of income and education in the time frame from 1990 to 2001. This study also 
found an increase in the percentage of overweight individuals from 27% to 40% 
(N=1169 adults). Reas et al. [17] concluded that accelerated weight gain occurs due 
to lifestyle changes (diet, energy expenditure), especially in younger adulthood. At the 
start of our study in 2007, the PCOS patients followed up were aged 26.5 ± 6.4, thus 
falling in the category of younger adults. Therefore, the possibility that the weight gain 
is solely associated with aging would be conclusive with the aforementioned 
Norwegian studies [16, 17].  
 
Insulin Resistance 
HOMA-IR values were used to assess IR. Our study did not show any 
statistically significant changes in HOMA-IR over the evaluated nine years (P = 0.967). 
The number of women with PCOS with HOMA-IR > 2.5% only increased by one until 
the year 2016 (P = 0.611). According to other studies there is evidence of clustering of 
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metabolic risk factors in metabolic syndrome and therefore the development of CVD 
[18, 19]. A Framingham Offspring Study with 2616 nondiabetic participants found that 
an increase in BMI, which is also present in our study, is especially strongly related to 
similar changes in other metabolic risk factors, especially IR [18]. With the presence of 
this correlation among all the metabolic parameters, a slightly more impressive change 
in IR could have been expected. This is also supported by the already well-known role 
of abdominal obesity in the development of IR [3, 6]. An even bigger change in IR 
would have probably been seen with an even greater increase in BMI. Additionally, 
Rutter et al. [18] found that changes in IR played an important role in the clustering of 
metabolic risk factors as well. On the other hand, this could explain why there was only 
a small change in our measured parameters over time. 
 
Lipids 
As previously mentioned, dyslipidemia is the most common metabolic 
abnormality in women with PCOS [10], even though it is also true that many patients 
have entirely normal lipid profiles [3]. The parameters of the lipidogram considered in 
this study were total-C, TG, and LDL-C which represent known risk factors of CVD, 
and the cardioprotective HDL-C. The results of our study showed that the respective 
values did not change in a statistically significant way. 
According to Diamanti-Kandarakis et al. [20] it is exceedingly difficult to establish a 
cause-effect relationship between the different cardiometabolic risk factors present in 
PCOS, even though obesity seems to be a major risk factor for developing 
dyslipidemia. This was supported by Robinson et al. [21] who observed in a different 
study that obesity is not the only inherent risk factor in PCOS predisposing to 
dyslipidemia. In their study, Diamanti-Kandarakis et al. [20] tested the influence of the 
antiandrogen receptor blocker flutamide on dyslipidemia in PCOS and found an 
improvement, hence supporting evidence of the role of hyperandrogenism in the 
development of dyslipidemia.  
 
CRP 
Our study did not show a significant increase in CRP levels, similar to the other 
metabolic parameters observed. 
A Finnish randomized clinical trial [22] examined the influences of therapy with 
metformin versus ethinyl estradiol-cyproterone acetate (EE-CA) oral contraceptive pills 
	 13	
(OCPs) in 20 non-obese and 32 obese women diagnosed with PCOS and increased 
CRP values over six months. A significantly higher CRP level was observed in obese 
compared to non-obese women. This difference remained during both treatments. The 
study showed a significant correlation (Pearson’s correlation) of CRP levels and BMI, 
WHR and waist circumference, as well at baseline as at six months of respective 
treatment. At six months, treatment with metformin resulted in a 31% decrease of CRP 
levels in non-obese subjects and a 56% decrease in obese subjects, proving its 
beneficial effects on metabolic and hormonal parameters, and implying a possible 
decrease in chronic inflammation. On the other hand, treatment with the EE-CA OCP 
lead to an increase in CRP levels after six months. This increase suggested it to be an 
unfitting treatment in especially obese women with IR diagnosed with PCOS. These 
results suggest that a lack of change in CRP levels could be due to the long-term 
treatment of our population. 
A meta-analysis of 26 studies matching for BMI established that the elevation 
of CRP is more notable in obese women with PCOS [23]. After adjusting the BMI, the 
elevation attributable to PCOS is relatively small. Therefore, there is a strong 
association between BMI and CRP elevation, and BMI reduction could help regulate 
CRP levels. This further supports results like those from our study, that even in long-
term follow-up no significant CRP changes need to be present. 
 
Other studies investigating cardiometabolic risk factors in PCOS and their 
correlation with mortality in a bigger population brought similar results. Iftikhar et al. 
[24] found few differences in cardiovascular (CV) risk factors and no overall difference 
in CV events in a retrospective cohort study comparing 309 women with PCOS to 343 
women without PCOS during a mean follow-up of 23 years. Pierpoint et al. [25] 
concluded in another long-term follow-up of 786 women with PCOS in the United 
Kingdom that there is no increase in mortality from CVD, even though the disease is 
strongly associated with important cardiometabolic risk factors. Wild et al. [26] did a 
similar retrospective study of 319 women diagnosed with PCOS, based on the fact that 
there is an increase in cardiometabolic risk factors compared to age-matched controls. 
The result of this study was also that there is no significant increase in CV mortality 
[26]. This could lead to the assumption that there was no significant increase in 
cardiometabolic parameters, and Wild et al. [26] speculated that a different etiology for 
coronary heart disease should be considered in women diagnosed with PCOS. All 
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these studies compared women with PCOS to women without PCOS, and only 
Schmidt et al. [4] analyzed the risk in a similar set of patients. In their study, they 
compared the cardiometabolic risk factors in pre- and perimenopausal women with 
PCOS. Schmidt et al. [4] concluded after the 21-year follow-up that the only more 
frequently persistent cardiometabolic risk factors in women with PCOS were 
hypertension and triglyceridemia. Altogether they did not observe an obvious increase 
in cardiovascular events during the post-menopausal period in PCOS patients [4].  
Generally, there are a few biases that could have largely influenced our results. 
Firstly, a relatively small population size was selected. Another factor that likely 
influenced our outcome was the duration of the study. Increasing the duration of follow 
up could increase the significance of our test results. Perhaps the outcome could be 
improved if we were to follow up the patients from diagnosis to the occurrence of a CV 
event, but this is difficult to accomplish, especially considering drop-out bias and other. 
Furthermore, it is important to mention that the metabolic parameters were not 
measured at the same laboratories in 2016. This could also have an influence on the 
precision of the test results. 
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9. Conclusions 
 
In conclusion, our results showed that there is a trend observed towards 
worsening of all cardiometabolic risk factors present in PCOS which were considered 
in this stud, but the changes did not show any statistical significance. Our results could 
have been influenced by different biases (observational study, small sample size, 
metabolic parameters measured in different laboratories). BMI was the only metabolic 
parameter that changed significantly during the nine years observed in this study, 
although less than expected. 
Further studies should be conducted and designed with larger sample sizes, 
longer time course of observation, more frequent follow ups and measurement in the 
same laboratories. Moreover, a comparison of pharmacological treatment of the PCOS 
patients and its relation to changes in metabolic parameters would be informative. 
Another idea to improve future studies would be to evaluate siblings and other family 
members of women with PCOS. 
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